AstraZeneca

NASDAQ: AZN · Real-Time Price · USD
78.84
0.37 (0.47%)
At close: Aug 15, 2025, 12:14 PM

AstraZeneca Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 30, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
56.5B 54.98B 54.07B 51.21B 49.13B 47.61B 45.81B 44.99B 44.48B 43.84B 44.35B 45.15B 44.04B 41.49B 37.42B 32.82B 29.53B 27.58B
Cost of Revenue
10.51B 10.22B 10.21B 9.79B 8.8B 8.58B 8.27B 8.86B 9.75B 10.79B 12.39B 14.12B 14.89B 14.08B 12.44B 9.34B 6.95B 5.74B
Gross Profit
45.99B 44.76B 43.87B 41.42B 40.33B 39.03B 37.54B 36.13B 34.74B 33.05B 31.96B 31.04B 29.15B 27.4B 24.98B 23.48B 22.58B 21.84B
Operating Income
11.32B 10.56B 10B 9.2B 9.05B 8.76B 8.19B 6.62B 5.91B 3.99B 2.32B 2.37B -549M 39M 1.06B 2.83B 5.68B 5.84B
Interest Income
399M 431M 458M 459M 377M 341M 308M 274M 188M 142M 81M 51M 51M 40M 43M 45M 37M 52M
Pretax Income
10.02B 9.29B 8.69B 7.92B 7.75B 7.44B 6.9B 6.78B 6.05B 4.21B 2.5B 1.09B -1.84B -1.32B -265M 1.54B 4.39B 4.59B
Net Income
8.29B 7.77B 7.04B 6.5B 6.44B 6.33B 5.96B 5.9B 6.16B 4.7B 3.29B 2.04B -1.25B -1.06B 112M 1.47B 3.77B 3.98B
Selling & General & Admin
20.42B 20.48B 20.53B 18.96B 18.6B 18.66B 18.22B 19.02B 18.49B 18.18B 18.95B 19.42B 18B 16.39B 14.46B 12.53B 11.82B 11.36B
Research & Development
14.5B 13.96B 13.58B 11.98B 11.45B 11.11B 10.94B 10.49B 10.26B 10.14B 9.66B 9.62B 9.41B 8.7B 8.28B 7.41B 6.71B 6.27B
Other Expenses
-256M -237M -185M -85M -60M n/a -138M -327M 622M 500M 541M -1.7B -352M -358M -1.44B 89M -2.05B -2.04B
Operating Expenses
34.66B 34.2B 33.86B 31.45B 30.51B 29.5B 28.82B 28.32B 27.47B 27.7B 28.04B 28.5B 29.35B 27.02B 23.58B 20.3B 16.75B 15.85B
Interest Expense
1.67B 1.68B 1.74B 1.72B 1.66B 1.64B 1.6B 1.53B 1.48B 1.36B 1.33B 1.3B 1.29B 1.31B 1.28B 1.25B 1.24B 1.24B
Selling & Marketing Expenses
563M 552M 555M 18.24B 18.22B 18.22B 18.22B 5.17B 5.17B 9.85B 14.68B 15.14B 18B 16.39B 14.46B 12.53B 11.82B 11.36B
Cost & Expenses
45.18B 44.42B 44.07B 41.23B 39.31B 38.08B 37.09B 37.18B 37.22B 38.49B 40.43B 42.62B 44.24B 41.1B 36.02B 29.64B 23.7B 21.59B
Income Tax Expense
1.72B 1.51B 1.65B 1.42B 1.3B 1.1B 938M 876M -118M -499M -792M -958M -588M -261M -380M 72M 624M 633M
Shares Outstanding (Basic)
3.1B 3.1B 3.1B 3.11B 3.11B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.09B 2.99B 2.62B 2.62B
Shares Outstanding (Diluted)
3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.09B 2.99B 2.64B 2.64B
EPS (Basic)
2.68 2.51 2.27 2.09 2.08 2.04 1.92 1.90 1.99 1.52 1.06 0.66 -0.42 -0.32 0.14 0.65 1.44 1.52
EPS (Diluted)
2.66 2.50 2.26 2.09 2.07 2.03 1.91 1.90 1.98 1.51 1.06 0.66 -0.42 -0.32 0.14 0.64 1.44 1.52
EBITDA
18.57B 17.73B 17.22B 14.96B 14.19B 13.75B 13.08B 13.27B 12.51B 10.79B 9.1B 8.59B 7.15B 7.07B 7.58B 7.96B 8.93B 9.04B
EBIT
11.74B 11.02B 10.43B 9.64B 9.4B 9.02B 8.43B 8.25B 7.45B 5.53B 3.79B 2.35B -562M -11M 1.01B 2.79B 5.63B 5.82B
Depreciation & Amortization
6.83B 6.72B 6.69B 5.22B 4.69B 4.69B 4.93B 5.31B 5.37B 5.45B 5.25B 6.19B 7.65B 7.04B 6.53B 5.13B 3.15B 3.1B